COVID-19 – Implications in the Management of Patients with T2D and CVD
Studies on COVID-19 are revealing that patients diagnosed with COVID-19 and who have type 2 diabetes and history of cardiovascular disease are showing increased complications. Listen to Dr. Anne Peters, an endocrinology, diabetes and metabolism specialist and Dr. Diana Issacs, an endocrine clinical pharmacy specialist discuss tackling COVID-19 in their practices, including telehealth tips on getting started, treatment plan considerations, and ways to help patients prepare.
2020 Episode 3 – COVID-19 – Implications in the Management of Patients with T2D and CVD
Dr. Anne L. Peters is a professor of clinical medicine at the Keck School of Medicine of the University of Southern California and the Director of the USC Clinical Diabetes Programs. She runs diabetes centers in Beverly Hills and in underserved East Los Angeles. In addition to her clinical work, she has been a PI on multiple grants and has written over 200 articles and 4 books. She has been on multiple guideline writing committees for both type 1 and type 2 diabetes. Her major interests involve translating research findings, from lifestyle interventions to technology, to people with diabetes throughout the socioeconomic spectrum.
Dr. Anne Peters
Dr. Diana Isaacs is the Continuous Glucose Monitoring (CGM) Program Coordinator and Endocrinology Clinical Pharmacy Specialist at the Cleveland Clinic Diabetes Center. Dr. Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. She is the 2020 Association of Diabetes Care & Education Specialists (ADCES) Diabetes Care and Education Specialist of the Year.
Dr. Diana Isaacs
